Many of the nonconfidential advances in our premier research and development pipeline are shared through an extensive list of peer-reviewed publications and posters presented at international conferences.
Medical and Scientific Publications
Narsoplimab (OMS721) Publications:
Narsoplimab is an investigational product not approved by any regulatory agency.
2021
Real world use of narsoplimab in a case of severe HSCT-TMA
Pantin JM, Billy A. Blood. 2021;138(suppl 1):4862.
View abstractLong-term Phase 2 efficacy of the MASP-2 inhibitor narsoplimab for treatment of severe IgA nephropathy
Lafayette R, Carroll K, Barratt J. J Am Soc Nephrol. 2021;32:B10.
View abstractReduction of urinary levels of lectin pathway complement components in an IgA vasculitis patient after MASP-2 inhibition with narsoplimab
Pérez-Alós L, Scionti K, Molyneux K, Barratt J, Garred P. J Am Soc Nephrol. 2021;32:498.
View abstractClinical pharmacology and population pharmacokinetic/pharmacodynamic modeling of lectin pathway inhibition by narsoplimab (OMS721)
Pullman W, Facius A, Lahu G, Freeman J. Kidney Diseases. 2021;7(suppl 1):70.
View abstractLectin pathway mediates complement activation by SARS-CoV-2 proteins
Ali YM, Ferrari M, Lynch NJ, et al. Front Immunol. 2021;12:714511.
View on PubMedNarsoplimab (OMS721) treatment contributes to improvements in organ function in adult patients with high-risk transplant-associated thrombotic microangiopathy
Perales M, Cairo M, Duarte R, et al. Oral presentation at: 26th European Hematology Association Congress; June 9-17, 2021; virtual.
View abstractNarsoplimab (OMS721), a MASP-2 inhibitor, for the treatment of adult hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA): Subgroup analyses
Rambaldi A, Claes K, Goh YT, et al. Bone Marrow Transplant. 2021;56:147-149.
View abstractClinical pharmacology and population pharmacokinetic/pharmacodynamic modeling of lectin pathway inhibition by narsoplimab (OMS721)
Pullman W, Facius A, Lahu G, Smyth B. Bone Marrow Transplant. 2021;56:300-301.
View abstractIn acute HSCT/BMT-TMA the activation of the lectin pathway induces C5b-9 formation on endothelial cells and favors microvascular thrombosis
Galbusera M, Gastoldi S, Noris M, Bresin E, Benigni A, Remuzzi G. Bone Marrow Transplant. 2021;56:295-297
View abstractNarsoplimab (OMS721), a MASP-2 inhibitor, for the treatment of adult hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA)
Khaled SK, Boelens JJ, Cairo MS, et al. Transplantation and Cellular Therapy. 2021;27(3):S24-S26.
View abstractMASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab
Elhadad S, Chapin J, Copertino D, Van Besien K, Ahamed J, Laurence J. Clin Exp Immunol. 2021;203(1):96-104.
2020
Development of pharmacodynamic assays to assess ex vivo MASP-2 inhibition and their use to characterize the pharmacodynamics of narsoplimab (OMS721) in humans and monkeys
Freeman J, Cummings J, Chuidian M, Dudler T. Blood. 2020;136(suppl 1):26-27.
View abstractEndothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab
Rambaldi A, Gritti G, Micò MC, et al. Immunobiology. 2020;225(6):152001.
View on PubMedSafety, tolerability, and effect of narsoplimab (OMS721), a novel MASP-2 inhibitor for the treatment of IgA nephropathy
Lafayette R, Rovin B, Floege J, et al. Kidney Int Rep. 2020;5(11):2032-2041.
View on PubMedInhibition of the lectin pathway of the complement system as a novel approach in the management of IgA vasculitis-associated nephritis
Selvaskandan H, Cheung CK, Dormer J, et al. Nephron. 2020;144(9):453-458.
View on PubMedNarsoplimab (OMS721) for the treatment of adult hematopoietic stem cell transplant-associated thrombotic microangiopathy
Rambaldi A, Smith M, Whitaker S, Khaled S. Oral presentation at: European Hematology Association Congress; June, 2020; virtual.
View abstractMASP-2 inhibition as a potential strategy for the management of IgA nephropathy
Barratt J, Lafayette R. Drugs of the Future. 2020;45(6):389-396.
View on journal website2019
MASP-2 levels following allogeneic hematopoietic stem cell transplantation in adults: correlation with development of a thrombotic microangiopathy and implications for therapy with anti-complement agents
Elhadad S, Van Biesen K, Chapin J, Ahamed J, Laurence J. Poster presented at: American Society of Hematology 2019 Annual Meeting; Dec 7-10, 2019; Orlando, FL.
View AbstractAbsence of the lectin activation pathway of complement ameliorates proteinuria-induced renal injury
Alghadban S, Kenawy HI, Dudler T, Schwaeble WJ, Bunskill NJ. Front Immunol. 2019;10:2238.
View on PubMedInterim results from an ongoing phase 2 study evaluating the use of a MASP-2 inhibitor for the treatment of IgA nephropathy
Barratt J, Leifke E, Whitaker S, et al. Presented at: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA); June, 2019; Budapest, HU.
2018
Cardioprotection by an anti-MASP-2 antibody in a murine model of myocardial infarction
Clark JE, Dudler T, Marber MS, Schwaeble W. Open Heart. 2018;5(1):e000652.
Improved survival following OMS721 treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA)
Rambaldi A, Khaled S, Smith M, et al. Presented at: European Hematology Association (EHA); June 15, 2018; Stockholm, Sweden.
2017
The effect of OMS721 on proteinuria in patients with IgA nephropathy
Block G, Whitaker S. Presented at: European Renal Association—European Dialysis and Transplant Association (ERA-EDTA); June 4, 2017; Madrid, Spain.
Maintenance of remission following completion of OMS721 treatment in Patients with IgA nephropathy (IgAN)
Block G, Whitaker S. Presented at: American Society of Nephrology (ASN); November 6, 2017; New Orleans, LA.
Effective treatment of GvHD-associated transplant-associated microangiopathy with a novel inhibitor of the lectin pathway of complement
Caprioli C, Grassi A, Micò C, Rambaldi A. Presented at: EBMT Transplant Complications Working Party – Crash Course on Diagnosis and Treatment of Noninfectious Complications after HCT: October 19-20, 2017; Granada, Spain.
Early results of a phase 2 study using OMS721 in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA)
Khaled SK, Kwong YL, Smith M, Metjian A, Whitaker S. Presented at: American Society of Blood and Marrow Transplantation (ASBMT); February 25, 2017; Orlando, FL.
Dose-finding clinical trial of OMS721 for the treatment of atypical hemolytic uremic syndrome (aHUS) – stage 1 results
Nowicki M, Wiecek A, Massart A, Weekers L, Whitaker S, Miglinas M. Presented at: World Congress of Nephrology (WCN); April 21-25, 2017; Mexico City, Mexico.
Lectin pathway effector enzyme mannan-binding lectin-associated serine protease-2 can activate native complement C3 in absence of C4 and/or C2
Yaseen S, Demopulos G, Dudler T, et al. FASEB J. 2017;31(5):2210-2219. doi:10.1096/fj.201601306R.
Resolution of acute kidney injury secondary to TA-TMA by the anti-MASP-2 monoclonal antibody OMS721 in a pediatric HSCT recipient
Zecca M, Comoli P, Mina T, et al. Bone Marrow Transplantation. 2017;52:S124-S516.
View abstract2016
Mannan binding lectin-associated serine protease-2 (MASP-2) critically contributes to post-ischemic brain injury independent of MASP-1
Orsini F, Chrysanthou E, Dudler T, et al. J Neuroinflammation. 2016;13(1):213. doi:10.1186/s12974-016-0684-6.
2014
Mannan-binding lectin-associated serine protease 2 is critical for the development of renal ischemia reperfusion injury and mediates tissue injury in the absence of complement C4
Asgari E, Farrar CA, Lynch N, et al. FASEB J. 2014;28(9):3996-4003.
View on PubMed2012
The lectin pathway of complement activation is a critical component of the innate immune response to pneumococcal infection
Ali YM, Lynch NJ, Haleem KS, et al. PLoS Pathog. 2012;8:e1002793.
View on PubMed2011
Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury
Schwaeble WJ1, Lynch NJ, Clark JE,et al. Proc Natl Acad Sci USA. 2011;108(18):7523-7528. doi:10.1073/pnas.1101748108.
View on PubMed2010
Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot
Gulla KC1, Gupta K, Krarup A, et al. Immunology. 2010;129(4):482-495. doi:10.1111/j.1365-2567.2009.03200.x.
View on PubMed
Other Publications:
Selective inhibition of phosphodiesterase 7 enzymes reduces motivation for nicotine use through modulation of mesolimbic dopaminergic transmission
Ciccocioppo R, de Guglielmo G, Li H, et al. J Neurosci. 2021;41(28):6128-6143. doi:10.1523/JNEUROSCI.3180-20.2021.
View on PubMedPPARγ activation attenuates opioid consumption and modulates mesolimbic dopamine transmission
de Guglielmo G, Melis M, De Luca MA, et al. Neuropsychopharmacology. 2015;40(4):927-937. doi:10.1038/npp.2014.268.
Selection of targeted mutants from a library of randomly mutagenized ES cells
Horie K, Gaitanaris G, Gragerov A. Methods Mol Biol. 2011;693:283-294. doi:10.1007/978-1-60761-974-1_17.
An inducible and reversible mouse genetic rescue system
Zeng H, Horie K, Madisen L, et al. PLoS Genet. 2008;4(5):e1000069. doi:10.1371/journal.pgen.1000069.
Neuromedin U receptor 2-deficient mice display differential responses in sensory perception, stress, and feeding
Zeng H, Gragerov A, Hohmann JG, et al. Mol Cell Biol. 2006;26(24):9352-9363.
Related Pages
